{"id":"qvm149","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This dual combination aims to improve glycemic control and weight loss by inhibiting glucagon and enhancing GLP-1 activity. By doing so, QVM149 may help to reduce blood glucose levels and promote weight reduction in patients with type 2 diabetes.","oneSentence":"QVM149 is a dual combination of a glucagon receptor antagonist and a glucagon-like peptide-1 (GLP-1) receptor agonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:31:00.065Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT05776927","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-05-29","conditions":"Asthma","enrollment":304},{"nctId":"NCT05274425","phase":"","title":"A 24-week rPMS Study in Real-world Setting for Enerzair","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-05-09","conditions":"Asthma","enrollment":600},{"nctId":"NCT04259164","phase":"PHASE3","title":"Anti-inflammatory Effects Glycopyrronium","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2020-09-10","conditions":"Asthma, Allergic Asthma","enrollment":28},{"nctId":"NCT04206761","phase":"PHASE3","title":"Investigating the Effects of QVM149 on MRI Ventilation Defects","status":"WITHDRAWN","sponsor":"Dr. Grace Parraga","startDate":"2021-12-01","conditions":"Asthma","enrollment":""},{"nctId":"NCT03158311","phase":"PHASE3","title":"Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-02-05","conditions":"Asthma","enrollment":1426},{"nctId":"NCT03063086","phase":"PHASE2","title":"Assess Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-01-21","conditions":"Asthma","enrollment":116},{"nctId":"NCT03108027","phase":"PHASE2","title":"Assess Bronchodilator Effect QVM149 Dosed Either in the Morning or Evening Compared to Placebo in Patients With Asthma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-06-26","conditions":"Asthma","enrollment":38},{"nctId":"NCT02571777","phase":"PHASE3","title":"Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-12-08","conditions":"Asthma","enrollment":3092},{"nctId":"NCT03100825","phase":"PHASE3","title":"A Long-term Safety Study of QVM149 in Japanese Patients With Asthma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-04-28","conditions":"Asthma","enrollment":96},{"nctId":"NCT03100500","phase":"PHASE3","title":"A Long-term Safety Study of QMF149 in Japanese Participants With Asthma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-04-25","conditions":"Asthma","enrollment":51}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE"},{"count":1,"reaction":"COUGH"},{"count":1,"reaction":"DYSPNOEA EXERTIONAL"},{"count":1,"reaction":"RESPIRATORY TRACT INFECTION"},{"count":1,"reaction":"SPUTUM DISCOLOURED"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["indacaterol acetate/glycopyrronium bromide/mometasone furoate","Mometasone/Indacaterol/Glycopyrronium","QVM149 150/50/160 μg once daily, delivered as powder in hard capsules via Concept1 inhaler"],"phase":"phase_3","status":"active","brandName":"QVM149","genericName":"QVM149","companyName":"Dr. Grace Parraga","companyId":"dr-grace-parraga","modality":"Small molecule","firstApprovalDate":"","aiSummary":"QVM149 is a dual combination of a glucagon receptor antagonist and a glucagon-like peptide-1 (GLP-1) receptor agonist. Used for Treatment of type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":4,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}